tradingkey.logo

IDMC Provides Positive Recommendation For Bio-Thera Solution's BAT4406F In Neuromyelitis Optica Spectrum Disorder Based On Interim Analysis Of Pivotal Phase II/III Trial

ReutersJul 2, 2025 12:12 PM

- Bio-Thera Solutions Ltd 688177.SS:

  • IDMC PROVIDES POSITIVE RECOMMENDATION FOR BIO-THERA SOLUTION'S BAT4406F (ADCC-ENHANCED ANTI-CD20 MAB) IN NEUROMYELITIS OPTICA SPECTRUM DISORDER BASED ON INTERIM ANALYSIS OF PIVOTAL PHASE II/III TRIAL

  • BIO-THERA SOLUTIONS LTD - TO CLOSE PATIENT ENROLLMENT AHEAD OF SCHEDULE

  • BIO-THERA SOLUTIONS LTD - IDMC RECOMMENDS EARLY TERMINATION OF BAT4406F TRIAL DUE TO EFFICACY

  • BIO-THERA SOLUTIONS LTD - TO FILE FOR REGULATORY APPROVAL FROM NMPA

  • BIO-THERA SOLUTIONS LTD - TO EXPLORE BAT4406F IN OTHER INDICATIONS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI